FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366983682> ?p ?o ?g. }

• W4366983682 endingPage "2002" @default.
• W4366983682 startingPage "1993" @default.
• W4366983682 abstract "Background/Aim: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in various types of cancer. We aimed to determine the safety and efficacy of mTOR inhibitor nab-sirolimus when combined with the immune checkpoint inhibitor nivolumab. Patients and Methods: Previously treated patients ≥18 years with confirmed diagnosis of advanced sarcoma or tumor with mutations in the mTOR pathway were treated with 3 mg/kg nivolumab intravenously every 3 weeks; escalating doses of nab-sirolimus at 56, 75 or 100 mg/m² were administered intravenously on days 8 and 15 beginning in cycle 2. The primary aim was to determine the maximum-tolerated dose; we also determined disease control, objective response, progression-free survival, overall survival, and correlation between response using Immune-related Response Evaluation Criteria for Solid Tumors (irRECIST) versus RECIST v1.1. Results: The maximum-tolerated dose was 100 mg/m². There were two patients with partial response, 12 with stable disease and 11 with progressive disease. Median progression-free and overall survival were 12 and 47 weeks, respectively. The best responders (partial responses) were patients with undifferentiated pleomorphic sarcoma with loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), tuberous sclerosis complex 2 (TSC2) mutation and estrogen receptor-positive leiomyosarcoma. Treatment-related adverse events of grade 3 or more included thrombocytopenia, oral mucositis, rash, hyperlipidemia and increased serum alanine aminotransferase. Conclusion: The data indicate that (i) treatment with nivolumab plus nab-sirolimus is safe with no unexpected adverse events; (ii) treatment outcome parameters were not improved by combining nivolumab with nab-sirolimus; and (iii) best responders were patients with undifferentiated pleomorphic sarcoma with PTEN loss and TSC2 mutation and estrogen receptor-positive leiomyosarcoma. Future direction in sarcoma research with nab-sirolimus will be biomarker-based (TSC1/2/mTOR, tumor mutational burden/mismatch repair deficiency etc.)." @default.
• W4366983682 created "2023-04-27" @default.
• W4366983682 creator A5002035729 @default.
• W4366983682 creator A5018623286 @default.
• W4366983682 creator A5030400987 @default.
• W4366983682 creator A5042559581 @default.
• W4366983682 creator A5053904101 @default.
• W4366983682 creator A5064055990 @default.
• W4366983682 creator A5072718710 @default.
• W4366983682 date "2023-04-25" @default.
• W4366983682 modified "2023-10-05" @default.
• W4366983682 title "A Phase I/II Investigation of Safety and Efficacy of Nivolumab and<i>nab</i>-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway" @default.
• W4366983682 doi "https://doi.org/10.21873/anticanres.16360" @default.
• W4366983682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37097693" @default.
• W4366983682 hasPublicationYear "2023" @default.
• W4366983682 type Work @default.
• W4366983682 citedByCount "2" @default.
• W4366983682 countsByYear W43669836822023 @default.
• W4366983682 crossrefType "journal-article" @default.
• W4366983682 hasAuthorship W4366983682A5002035729 @default.
• W4366983682 hasAuthorship W4366983682A5018623286 @default.
• W4366983682 hasAuthorship W4366983682A5030400987 @default.
• W4366983682 hasAuthorship W4366983682A5042559581 @default.
• W4366983682 hasAuthorship W4366983682A5053904101 @default.
• W4366983682 hasAuthorship W4366983682A5064055990 @default.
• W4366983682 hasAuthorship W4366983682A5072718710 @default.
• W4366983682 hasBestOaLocation W43669836821 @default.
• W4366983682 hasConcept C121608353 @default.
• W4366983682 hasConcept C126322002 @default.
• W4366983682 hasConcept C143998085 @default.
• W4366983682 hasConcept C183713625 @default.
• W4366983682 hasConcept C190283241 @default.
• W4366983682 hasConcept C197934379 @default.
• W4366983682 hasConcept C2776694085 @default.
• W4366983682 hasConcept C2776820818 @default.
• W4366983682 hasConcept C2777609662 @default.
• W4366983682 hasConcept C2777701055 @default.
• W4366983682 hasConcept C2777793932 @default.
• W4366983682 hasConcept C2777921159 @default.
• W4366983682 hasConcept C2778822529 @default.
• W4366983682 hasConcept C2779699572 @default.
• W4366983682 hasConcept C2779984678 @default.
• W4366983682 hasConcept C2780030458 @default.
• W4366983682 hasConcept C502942594 @default.
• W4366983682 hasConcept C55493867 @default.
• W4366983682 hasConcept C71924100 @default.
• W4366983682 hasConcept C86554907 @default.
• W4366983682 hasConcept C86803240 @default.
• W4366983682 hasConcept C90924648 @default.
• W4366983682 hasConceptScore W4366983682C121608353 @default.
• W4366983682 hasConceptScore W4366983682C126322002 @default.
• W4366983682 hasConceptScore W4366983682C143998085 @default.
• W4366983682 hasConceptScore W4366983682C183713625 @default.
• W4366983682 hasConceptScore W4366983682C190283241 @default.
• W4366983682 hasConceptScore W4366983682C197934379 @default.
• W4366983682 hasConceptScore W4366983682C2776694085 @default.
• W4366983682 hasConceptScore W4366983682C2776820818 @default.
• W4366983682 hasConceptScore W4366983682C2777609662 @default.
• W4366983682 hasConceptScore W4366983682C2777701055 @default.
• W4366983682 hasConceptScore W4366983682C2777793932 @default.
• W4366983682 hasConceptScore W4366983682C2777921159 @default.
• W4366983682 hasConceptScore W4366983682C2778822529 @default.
• W4366983682 hasConceptScore W4366983682C2779699572 @default.
• W4366983682 hasConceptScore W4366983682C2779984678 @default.
• W4366983682 hasConceptScore W4366983682C2780030458 @default.
• W4366983682 hasConceptScore W4366983682C502942594 @default.
• W4366983682 hasConceptScore W4366983682C55493867 @default.
• W4366983682 hasConceptScore W4366983682C71924100 @default.
• W4366983682 hasConceptScore W4366983682C86554907 @default.
• W4366983682 hasConceptScore W4366983682C86803240 @default.
• W4366983682 hasConceptScore W4366983682C90924648 @default.
• W4366983682 hasIssue "5" @default.
• W4366983682 hasLocation W43669836821 @default.
• W4366983682 hasLocation W43669836822 @default.
• W4366983682 hasOpenAccess W4366983682 @default.
• W4366983682 hasPrimaryLocation W43669836821 @default.
• W4366983682 hasRelatedWork W1878218305 @default.
• W4366983682 hasRelatedWork W2000110198 @default.
• W4366983682 hasRelatedWork W2018022997 @default.
• W4366983682 hasRelatedWork W2109706412 @default.
• W4366983682 hasRelatedWork W2141443930 @default.
• W4366983682 hasRelatedWork W2279823231 @default.
• W4366983682 hasRelatedWork W2968827568 @default.
• W4366983682 hasRelatedWork W4240184164 @default.
• W4366983682 hasRelatedWork W4366983682 @default.
• W4366983682 hasRelatedWork W96337941 @default.
• W4366983682 hasVolume "43" @default.
• W4366983682 isParatext "false" @default.
• W4366983682 isRetracted "false" @default.
• W4366983682 workType "article" @default.